207 related articles for article (PubMed ID: 38180008)
1. Overcoming brain barriers through surface-functionalized liposomes for glioblastoma therapy; current status, challenges and future perspective.
Dong C; Yu X; Jin K; Qian J
Nanomedicine (Lond); 2023 Dec; 18(30):2161-2184. PubMed ID: 38180008
[TBL] [Abstract][Full Text] [Related]
2. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
3. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model.
Lakkadwala S; Singh J
Colloids Surf B Biointerfaces; 2019 Jan; 173():27-35. PubMed ID: 30261346
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
Wang D; Wang C; Wang L; Chen Y
Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
[TBL] [Abstract][Full Text] [Related]
6. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
7. Overcoming biological barriers BBB/BBTB by designing PUFA functionalised lipid-based nanocarriers for glioblastoma targeted therapy.
Zwain T; Alder JE; Zwayen S; Shaw A; Burrow AJ; Singh KK
Biomater Adv; 2023 Dec; 155():213660. PubMed ID: 37976832
[TBL] [Abstract][Full Text] [Related]
8. Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma.
Lakkadwala S; Dos Santos Rodrigues B; Sun C; Singh J
J Control Release; 2019 Aug; 307():247-260. PubMed ID: 31252036
[TBL] [Abstract][Full Text] [Related]
9. Liposomal Carrier Conjugated to APP-Derived Peptide for Brain Cancer Treatment.
Gabay M; Weizman A; Zeineh N; Kahana M; Obeid F; Allon N; Gavish M
Cell Mol Neurobiol; 2021 Jul; 41(5):1019-1029. PubMed ID: 33025416
[TBL] [Abstract][Full Text] [Related]
10. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery.
Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W
J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902
[TBL] [Abstract][Full Text] [Related]
11. Overcoming Barriers in Glioblastoma-Advances in Drug Delivery Strategies.
Ter Linden E; Abels ER; van Solinge TS; Neefjes J; Broekman MLD
Cells; 2024 Jun; 13(12):. PubMed ID: 38920629
[TBL] [Abstract][Full Text] [Related]
12. Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies.
Balça-Silva J; Matias D; Carmo AD; Sarmento-Ribeiro AB; Lopes MC; Moura-Neto V
Semin Cancer Biol; 2019 Oct; 58():130-141. PubMed ID: 30266571
[TBL] [Abstract][Full Text] [Related]
13. Multi-ligand functionalized blood-to-tumor sequential targeting strategies in the field of glioblastoma nanomedicine.
Martins C; Sarmento B
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1893. PubMed ID: 37186374
[TBL] [Abstract][Full Text] [Related]
14. Targeting brain tumors with innovative nanocarriers: bridging the gap through the blood-brain barrier.
Wadhwa K; Chauhan P; Kumar S; Pahwa R; Verma R; Goyal R; Singh G; Sharma A; Rao N; Kaushik D
Oncol Res; 2024; 32(5):877-897. PubMed ID: 38686045
[TBL] [Abstract][Full Text] [Related]
15. Validation of Thiosemicarbazone Compounds as P-Glycoprotein Inhibitors in Human Primary Brain-Blood Barrier and Glioblastoma Stem Cells.
Salaroglio IC; Abate C; Rolando B; Battaglia L; Gazzano E; Colombino E; Costamagna C; Annovazzi L; Mellai M; Berardi F; Capucchio MT; Schiffer D; Riganti C
Mol Pharm; 2019 Aug; 16(8):3361-3373. PubMed ID: 31265310
[TBL] [Abstract][Full Text] [Related]
16. A state-of-the-art liposome technology for glioblastoma treatment.
Hasan I; Roy S; Ehexige E; Wu R; Chen Y; Gao Z; Guo B; Chang C
Nanoscale; 2023 Nov; 15(45):18108-18138. PubMed ID: 37937394
[TBL] [Abstract][Full Text] [Related]
17. Dual Functionalized 5-Fluorouracil Liposomes as Highly Efficient Nanomedicine for Glioblastoma Treatment as Assessed in an In Vitro Brain Tumor Model.
Lakkadwala S; Singh J
J Pharm Sci; 2018 Nov; 107(11):2902-2913. PubMed ID: 30055226
[TBL] [Abstract][Full Text] [Related]
18. The functional curcumin liposomes induce apoptosis in C6 glioblastoma cells and C6 glioblastoma stem cells in vitro and in animals.
Wang Y; Ying X; Xu H; Yan H; Li X; Tang H
Int J Nanomedicine; 2017; 12():1369-1384. PubMed ID: 28260885
[TBL] [Abstract][Full Text] [Related]
19. Functionalized liposomes: an enticing nanocarrier for management of glioma.
Peddinti V; Rout B; Agnihotri TG; Gomte SS; Jain A
J Liposome Res; 2024 Jun; 34(2):349-367. PubMed ID: 37855432
[TBL] [Abstract][Full Text] [Related]
20. PAMAM Dendrimer Nanomolecules Utilized as Drug Delivery Systems for Potential Treatment of Glioblastoma: A Systematic Review.
Fana M; Gallien J; Srinageshwar B; Dunbar GL; Rossignol J
Int J Nanomedicine; 2020; 15():2789-2808. PubMed ID: 32368055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
